One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy:: A prospective randomized controlled trial

被引:0
|
作者
Kung, NNS [1 ]
Sung, JJY
Yuen, NWF
Li, TH
Ng, PW
Lai, WM
Lui, YH
Lam, KN
Choi, CH
Leung, MF
机构
[1] United Christian Hosp, Dept Med, 130 Hip Wo St, Kowloon, Peoples R China
[2] United Christian Hosp, Dept Pathol, Kowloon, Peoples R China
[3] United Christian Hosp, Dept Microbiol, Kowloon, Peoples R China
[4] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med, Shatin, Peoples R China
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 1999年 / 94卷 / 03期
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: The efficacy of 1 wk bismuth triple therapy is adversely influenced by the presence of metronidazole resistance. In vitro studies suggest that ranitidine bismuth citrate (RBC) plus metronidazole exhibit synergistic activity against metronidazole resistant strains of Helicobacter pylori (H. pylori). Whether this confers a superior clinical efficacy remains unproven. This study compared the efficacy of RBC-based triple therapy with bismuth triple therapy in eradication of H. pylori. METHODS: Patients with H. pylori-related ulcer disease or gastritis were randomized to receive either 400/mg of RBC twice daily plus 400/mg of metronidazole and 500/mg of tetracycline four times daily for 1 wk (RMT) or 120/mg of colloidal bismuth subcitrate, 400/mg of metronidazole, and 500/mg of tetracycline, all given four times daily for 1 wk (BMT). Metronidazole susceptibility was determined by the E-test and pretreatment resistance was defined as minimum inhibitory concentration greater than or equal to 32/mg/L. RESULTS: Of 100 consecutive patients randomized, two patients were lost to follow-up in each group. Forty-three of 85 (51%) H. pylori isolates were metronidazole resistant. Perprotocol cure rate for RMT and BMT was 49 of 41 (98%) and 37 of 44 (84%), respectively (p = 0.058). Intent-to-treat cure rate for RMT and BMT was 46 of 50 and 41 of 50, respectively (92% vs 82%,p = 0.23). A significantly higher eradication of metronidazole resistant H. pylori was observed in the RMT group (25 of 25, 100%) than in the BMT group (12 of 16, 75%), (p = 0.018). Side effects observed in the two treatment groups were comparable. CONCLUSIONS: One week of RBC triple therapy with metronidazole and tetracycline is an effective anti-Helicobacter therapy. This regimen is more appropriate in areas of high prevalence of metronidazole resistance. (Am J Gastroenterol 1999;94:721-724. (C) 1999 by Am. Cell. of Gastroenterology).
引用
收藏
页码:721 / 724
页数:4
相关论文
共 50 条
  • [1] One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection:: A randomized, clinical trial
    van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1998, 93 (08): : 1228 - 1231
  • [2] Prospective randomized comparisons of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (Denol)-based triple therapy for the treatment of H-pylori infection.
    Kung, NNS
    Sung, JY
    Yuen, WF
    Li, TH
    Ng, PW
    Lai, WM
    Leung, MF
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : A190 - A190
  • [3] One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese
    Hung, WK
    Wong, WM
    Wong, GSW
    Yip, AWC
    Szeto, ML
    Lai, KC
    Hu, WHC
    Chan, CK
    Xia, HHX
    Yuen, MF
    Fung, FMY
    Tong, TSM
    Ho, VYK
    Lam, SK
    Wong, BCY
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (12) : 2067 - 2072
  • [4] A prospective randomized trial of one-week bismuth ranitidine citrate (RBC) triple therapies for H-pylori infection.
    Sung, JJY
    Chan, FKL
    Leung, WK
    Wu, JCY
    Suen, R
    Ling, TKW
    Lee, YT
    Cheng, AFB
    Chung, SCS
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A321 - A321
  • [5] One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication
    Gisbert, JP
    Carpio, D
    Marcos, S
    Gisbert, JL
    Grávalos, RG
    Pajares, JM
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (05) : 489 - 495
  • [6] One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance
    Wong, BCY
    Wong, WM
    Wang, WH
    Fung, FMY
    Lai, KC
    Chu, KM
    Yuen, ST
    Leung, SY
    Hu, WHC
    Yuen, MF
    Lau, GKK
    Chan, CK
    Lam, SK
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (03) : 403 - 409
  • [7] Eradication of Helicobacter pylori using one-week therapy combining ranitidine bismuth citrate with two antibiotics.
    Savarino, V
    Mansi, C
    Mele, MR
    Bisso, G
    Mela, GS
    Saggioro, A
    Caroli, M
    Vigneri, S
    Termini, R
    Olivieri, A
    Tosatto, R
    Celle, G
    [J]. GASTROENTEROLOGY, 1997, 112 (04) : A280 - A280
  • [8] One-week therapy with omeprazole or ranitidine bismuth citrate plus clarithromycin and and amoxicillin for treatment of Helicobacter pylori infection.
    Rojas, M
    Hergueta, P
    Romero, R
    Gomez, BJ
    Pellicer, FJ
    Herrerias, JM
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A1300 - A1300
  • [9] Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection
    Mönkemüller, KE
    Hirschowitz, BI
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (05) : 661 - 665
  • [10] One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer
    Mesquita, Maria Aparecida
    Silva Lorena, Sonia Leticia
    Souza Almeida, Jazon Romilson
    Montes, Ciro Garcia
    Guerrazzi, Fabio
    Campos, Luciana T.
    Rubiota Zeitune, Jose Murilo
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (23) : 3566 - 3569